Business & Industry

On December 22, 2025, the news has been confirmed of Samsung Biologics to Buy US Drug Plant which is going to be its first US drug production facility from GSK plc for $280 million in order to reduce risks...

Optimize late-stage pharmaceutical assets through strategic investment planning, risk management, and indication prioritization. Maximize R&D return on investment during the highest-stakes phase of drug development.

Accelerate pharmaceutical R&D decision-making by implementing modern governance frameworks that establish clear decision rights, defined escalation pathways and cross-functional ownership while maintaining strategic alignment and rigor.

Novartis, which is a leading global innovative medicines company, went ahead and announced on December 19, 2025, that it has reached an agreement along with the US government that aims to lower innovative medicines price in the US and also...

President Donald Trump on December 19, 2025, said that his administration has reached agreements with nine additional pharmaceutical companies, therefore extending a campaign that is aimed at decreasing the prescription drug prices for certain Americans while at the same...

The U.S. Food and Drug Administration – FDA on December 22, 2025, gave an approval to the first GLP-1 pill for obesity from Novo Nordisk, the Wegovy maker. This can surely be called a landmark decision, which, as per health...

Risk management in pharma is often treated as a reactive compliance box-ticking exercise. This article argues for reframing risk as a strategic competitive advantage. It details proactive frameworks like the "Excipient Exclusion Filter," Decision Quality (DQ) matrices, and "pre-mortem" analyses that allow development teams to anticipate failure modes and engineer them out of the pipeline before they occur.